Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Hydrocodone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 known ✓ | P41143 | 12/20 | 1.00 |
| ▸ | OPRM1 known ✓ | P35372 | 11/20 | 1.00 |
| ▸ | OPRK1 known ✓ | P41145 | 8/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 1/20 | 1.00 |
| ▸ | MRGPRX2 | Q96LB1 | 1/20 | 1.00 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrocodone SCHEMBL12638883 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1LMNAPDE4D | |
| Hydrocodone SCHEMBL2987 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1LMNAPDE4D | |
| Hydrocodone SCHEMBL17523150 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1LMNAPDE4D | |
| Hydrocodone SCHEMBL101731 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1LMNAPDE4D | |
| Hydrocodone SCHEMBL12013631 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1LMNAPDE4D | |
| Hydrocodone SCHEMBL6744988 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1LMNAPDE4D | |
| Hydrocodone SCHEMBL12402839 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1LMNAPDE4D | |
| Hydrocodone SCHEMBL277572 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1LMNAPDE4D | |
| Hydrocodone SCHEMBL21335350 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1LMNAPDE4D | |
| Hydrocodone SCHEMBL12369421 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1LMNAPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11173209-B2 | Compositions for drug administration | AEGIS THERAPEUTICS, LLC (US) | 2021-11-16 | — | — | US | disclosed |
| US-10758478-B2 | Active agent loaded uniform, rigid, spherical, nanoporous calcium phosphate particles and methods of making and using the same | LABORATORY SKIN CARE, INC. (US) | 2020-09-01 | — | — | US | disclosed |
| US-20200138956-A1 | COMPOSITIONS FOR DRUG ADMINISTRATION | AEGIS THERAPEUTICS, LLC | 2020-05-07 | — | — | US | disclosed |
| US-10576156-B2 | Compositions for drug administration | AEGIS THERAPEUTICS, LLC (US) | 2020-03-03 | — | — | US | disclosed |
| US-10406153-B2 | Process for the preparation of benzhydrocodone hydrochloride | NORAMCO, INC. (US) | 2019-09-10 | — | — | US | disclosed |
| US-20190209551-A1 | ORAL DOSAGE FORMS FOR OXYGEN-CONTAINING ACTIVE AGENTS AND OXYL-CONTAINING POLYMER | SPRIASO LLC (US) | 2019-07-11 | — | — | US | disclosed |
| US-10208054-B2 | Method of preparing buprenorphine | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2019-02-19 | — | — | US | disclosed |
| US-20190046523-A1 | OLIGOMER-OPIOID AGONIST CONJUGATES | NEKTAR THERAPEUTICS | 2019-02-14 | — | — | US | disclosed |
| US-20180169247-A1 | COMPOSITIONS FOR DRUG ADMINISTRATION | AEGIS THERAPEUTICS, LLC | 2018-06-21 | — | — | US | disclosed |
| US-9981978-B2 | Preparation of saturated ketone morphinan compounds by catalytic isomerisation | CAMBREX CHARLES CITY, INC. (US) | 2018-05-29 | — | — | US | disclosed |
| US-8575196-B2 | Oligomer-opioid agonist conjugates | NEKTAR THERAPEUTICS (US) | 2013-11-05 | — | — | US | disclosed |
| EP-2628489-A1 | PEG oligomer-fentanyl conjugates | Nektar Therapeutics (US) | 2013-08-21 | — | — | EP | disclosed |
| US-8383815-B2 | Heterogeneous ruthenium metal catalyst for the production of hydrocodone, hydromorphone or a derivative thereof | MALLINCKRODT LLC (US) | 2013-02-26 | — | — | US | disclosed |
| US-20120184581-A1 | Oligomer-Opioid Agonist Conjugates | NEKTAR THERAPEUTICS (US) | 2012-07-19 | — | — | US | disclosed |
| US-7999104-B2 | Methods for one-pot N-demethylation/N-acylation of morphine and tropane alkaloids | BROCK UNIVERSITY (CA) | 2011-08-16 | — | — | US | disclosed |
| US-20110071016-A1 | Heterogeneous Ruthenium Metal Catalyst for the Production of Hydrocodone, Hydromorphone or a Derivative Thereof | MALLINCKRODT INC. (US) | 2011-03-24 | — | — | US | disclosed |
| US-20100286186-A1 | NOVEL DICARBOXYLIC ACID LINKED AMINO ACID AND PEPTIDE PRODRUGS OF OPIOIDS AND USES THEREOF | SHIRE LLC (US) | 2010-11-11 | — | — | US | disclosed |
| WO-2010112942-A1 | NOVEL DICARBOXYLIC ACID LINKED AMINO ACID AND PEPTIDE PRODRUGS OF OPIOIDS AND USES THEREOF | SHIRE LLC (US) | 2010-10-07 | — | — | WO | disclosed |
| WO-2010039560-A2 | ACTIVE AGENT LOADED UNIFORM, RIGID, SPHERICAL, NANOPOROUS CALCIUM PHOSPHATE PARTICLES AND METHODS OF MAKING AND USING THE SAME | LABORATORY SKIN CARE, INC. (US) | 2010-04-08 | — | — | WO | disclosed |
| US-20090005565-A1 | METHODS FOR ONE-POT N-DEMETHYLATION/N-ACYLATION OF MORPHINE AND TROPANE ALKALOIDS | BROCK UNIVERSITY | 2009-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11173209-B2 | Compositions for drug administration | SLC10A1, ABCB11, CSGALNACT1 | OPRD1 3158/4885OPRM1 2050/4885OPRK1 2869/4885 |
| US-20100286186-A1 | NOVEL DICARBOXYLIC ACID LINKED AMINO ACID AND PEPTIDE PRODRUGS OF OPIOIDS AND USES THEREOF | VIP, OPRL1, OPRK1 | OPRD1 6/4885OPRM1 4/4885OPRK1 3/4885 |
| US-20180169247-A1 | COMPOSITIONS FOR DRUG ADMINISTRATION | SLC10A1, ABCB11, CSGALNACT1 | OPRD1 3158/4885OPRM1 2050/4885OPRK1 2869/4885 |
| US-20190046523-A1 | OLIGOMER-OPIOID AGONIST CONJUGATES | OPRM1, OPRL1, OPRK1 | OPRD1 5/4885OPRM1 1/4885OPRK1 3/4885 |
| US-20110071016-A1 | Heterogeneous Ruthenium Metal Catalyst for the Production of Hydrocodone, Hydromorphone or a Derivative Thereof | OPRK1, OPRM1, OPRD1 | OPRD1 3/4885OPRM1 2/4885OPRK1 1/4885 |
| US-20190209551-A1 | ORAL DOSAGE FORMS FOR OXYGEN-CONTAINING ACTIVE AGENTS AND OXYL-CONTAINING POLYMER | OGFR, OPRL1, OGFRL1 | OPRD1 6/4885OPRM1 4/4885OPRK1 5/4885 |
| US-10758478-B2 | Active agent loaded uniform, rigid, spherical, nanoporous calcium phosphate particles and methods of making and using the same | CHERP, ORAI1, CA2 | OPRD1 4265/4885OPRM1 4536/4885OPRK1 4306/4885 |
| US-20200138956-A1 | COMPOSITIONS FOR DRUG ADMINISTRATION | SLC10A1, ABCB11, CSGALNACT1 | OPRD1 3158/4885OPRM1 2050/4885OPRK1 2869/4885 |
| US-10406153-B2 | Process for the preparation of benzhydrocodone hydrochloride | DBH, DHPS, PAH | OPRD1 27/4885OPRM1 74/4885OPRK1 34/4885 |
| US-20120184581-A1 | Oligomer-Opioid Agonist Conjugates | OPRM1, OPRL1, OPRK1 | OPRD1 5/4885OPRM1 1/4885OPRK1 3/4885 |
| US-20090005565-A1 | METHODS FOR ONE-POT N-DEMETHYLATION/N-ACYLATION OF MORPHINE AND TROPANE ALKALOIDS | HNMT, PNMT, NNMT | OPRD1 18/4885OPRM1 6/4885OPRK1 12/4885 |
| US-10576156-B2 | Compositions for drug administration | SLC10A1, ABCB11, CSGALNACT1 | OPRD1 3158/4885OPRM1 2050/4885OPRK1 2869/4885 |
| US-10208054-B2 | Method of preparing buprenorphine | OPRK1, OPRM1, OPRD1 | OPRD1 3/4885OPRM1 2/4885OPRK1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.